X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pcsk9 (1488) 1488
humans (1207) 1207
cholesterol (864) 864
hypercholesterolemia (651) 651
cardiac & cardiovascular systems (577) 577
male (560) 560
statins (515) 515
familial hypercholesterolemia (496) 496
female (493) 493
proprotein convertase 9 (477) 477
lipids (467) 467
low density lipoproteins (440) 440
atherosclerosis (416) 416
animals (395) 395
middle aged (380) 380
cholesterol, ldl - blood (377) 377
pcsk9 inhibitors (355) 355
peripheral vascular disease (355) 355
cardiovascular disease (346) 346
pharmacology & pharmacy (333) 333
biochemistry & molecular biology (320) 320
density-lipoprotein cholesterol (308) 308
lipoproteins (306) 306
ldl cholesterol (303) 303
risk factors (302) 302
monoclonal-antibody (295) 295
risk (284) 284
subtilisin/kexin type 9 (280) 280
safety (267) 267
efficacy (263) 263
mice (257) 257
ldl (250) 250
aged (247) 247
ldl receptor (238) 238
adult (235) 235
mutations (233) 233
serine endopeptidases - genetics (232) 232
mutation (230) 230
evolocumab (229) 229
ezetimibe (227) 227
alirocumab (226) 226
heterozygous familial hypercholesterolemia (225) 225
cardiovascular (217) 217
cardiovascular diseases (216) 216
receptors, ldl - metabolism (213) 213
proprotein convertase 9 - antagonists & inhibitors (205) 205
statin therapy (201) 201
coronary-heart-disease (198) 198
endocrinology & metabolism (197) 197
hypercholesterolemia - drug therapy (197) 197
ldl-c (192) 192
ldl-cholesterol (189) 189
anticholesteremic agents - therapeutic use (187) 187
double-blind (186) 186
serine endopeptidases - metabolism (184) 184
low density lipoprotein (182) 182
monoclonal antibodies (177) 177
abridged index medicus (176) 176
dyslipidemia (171) 171
receptors, ldl - genetics (171) 171
proprotein convertases (169) 169
genetic aspects (168) 168
expression (167) 167
treatment outcome (167) 167
disease (166) 166
autosomal-dominant hypercholesterolemia (163) 163
proprotein convertase subtilisin/kexin type 9 (161) 161
analysis (157) 157
metabolism (157) 157
reducing lipids (156) 156
research (153) 153
density-lipoprotein receptor (152) 152
cardiovascular-disease (151) 151
subtilisin (147) 147
antibodies, monoclonal - therapeutic use (146) 146
degradation (146) 146
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (146) 146
kexin (146) 146
biomarkers - blood (142) 142
statin (142) 142
ldlr (141) 141
proprotein convertase 9 - metabolism (140) 140
therapy (137) 137
cardiology (134) 134
diabetes (134) 134
medicine, general & internal (134) 134
atorvastatin (133) 133
hyperlipoproteinemia type ii - genetics (133) 133
care and treatment (131) 131
clinical trials (131) 131
coronary heart disease (130) 130
liver (130) 130
low-density lipoprotein cholesterol (126) 126
medicine & public health (126) 126
proprotein convertases - metabolism (123) 123
health aspects (120) 120
proprotein convertases - genetics (120) 120
low-density-lipoprotein (118) 118
prevention (115) 115
cardiovascular risk (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2312) 2312
Chinese (38) 38
German (38) 38
Spanish (31) 31
French (25) 25
Japanese (24) 24
Russian (14) 14
Czech (11) 11
Portuguese (7) 7
Italian (5) 5
Korean (4) 4
Polish (3) 3
Slovak (3) 3
Slovenian (3) 3
Greek (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
Biochemical Journal, ISSN 0264-6021, 05/2009, Volume 419, Issue 3, pp. 577 - 584
PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined... 
Surface plasmon resonance | Protein-protein interaction | Low-density lipoprotein receptor | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Antibody-mediated disruption | Cholesterol | FAMILIAL HYPERCHOLESTEROLEMIA | low-density lipoprotein receptor | LDL RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | antibody-mediated disruption | SECRETED PCSK9 | MUTANTS | PLASMA-CHOLESTEROL | GENE | surface plasmon resonance | cholesterol | DEGRADATION | protein-protein interaction | MICE | MUTATIONS | EXPRESSION | proprotein convertase subtilisin/kexin type 9 (PCSK9) | Cell Line | Reproducibility of Results | Humans | Insecta | Extracellular Space - drug effects | Models, Molecular | Receptors, LDL - metabolism | Mutant Proteins - metabolism | Epitopes | Antibodies - pharmacology | Extracellular Space - metabolism | Animals | Protein Binding - drug effects | Cholesterol, LDL - metabolism | Serine Endopeptidases - metabolism | Kinetics | Proprotein Convertases | Serine Endopeptidases - isolation & purification | Proprotein Convertase 9 | kexin type 9 | proprotein convertase subtilisin | BODIPY®, boron dipyrromethene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene | LDLc, LDL-cholesterol | FBS, fetal bovine serum | protein–protein interaction | kexin type 9 (PCSK9) | LDLR, LDL receptor | CHRD, cysteine | histidine-rich domain | MOI, multiplicity of infection | PCSK9, proprotein convertase subtilisin | RU, resonance units | HEK-F cells, Freestyle™ suspension human embryonic kidney cells | aa, amino acids | EGF-A, epidermal growth factor-like repeat A | LDL, low-density lipoprotein | SPR, surface plasmon resonance | IL1Ra, interleukin-1 receptor antagonist
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 62, Issue 16, pp. 1401 - 1408
Hypercholesterolemia is a major risk factor for cardiovascular diseases, increasing the incidence of myocardial infarction and death. Statin-induced lowering... 
Cardiovascular | Internal Medicine | atherosclerosis | proprotein convertase subtilisin/kexin type 9 | PCSK9 | LDL cholesterol | LDL receptor | atherosclerosis LDL cholesterol LDL receptor PCSK9 proprotein convertase subtilisin/kexin type 9 | NONHUMAN-PRIMATES | LDL-CHOLESTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | DENSITY-LIPOPROTEIN-CHOLESTEROL | SECRETED PCSK9 | RECEPTOR-MEDIATED ENDOCYTOSIS | STATIN THERAPY | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | SERINE-PROTEASE | Proprotein Convertases - antagonists & inhibitors | Dyslipidemias - complications | Humans | Lipoproteins, LDL - genetics | Proprotein Convertases - genetics | Molecular Targeted Therapy - trends | Serine Endopeptidases - genetics | Lipid Metabolism - genetics | Lipoproteins, LDL - metabolism | Molecular Targeted Therapy - methods | Receptors, LDL - genetics | Dyslipidemias - drug therapy | Atherosclerosis - drug therapy | Proprotein Convertases - metabolism | Risk Factors | Receptors, LDL - metabolism | Atherosclerosis - complications | Hypolipidemic Agents - pharmacology | Forecasting | Atherosclerosis - metabolism | Lipid Metabolism - drug effects | Dyslipidemias - metabolism | Serine Endopeptidases - metabolism | Mutation | Proprotein Convertase 9 | Hypertension | Hypercholesterolemia | Low density lipoproteins | Mortality | Atherosclerosis | Drug therapy | Statins | Cholesterol | Protein binding | Studies | Rodents
Journal Article
Journal Article
European heart journal, ISSN 1522-9645, 2017, Volume 38, Issue 32, pp. 2459 - 2472
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 63, Issue 13, pp. 1278 - 1288
Journal Article
European heart journal, ISSN 1522-9645, 2015, Volume 36, Issue 36, pp. 2425 - 2437
Journal Article